Immunological Potency, Efficacy, and Tolerance of “Gam-COVID-Vac” Vaccine among Students: Prospective Study

Background. Students, as the most active and mobile part of population, often unite into educational and informal groups, move to other regions or countries, and present a specific risk group for the spread of new coronavirus infection. Thus, they require preventive vaccination. objective. The aim of the study is to study the immunological potency, tolerance, and efficacy of Gam-COVID-Vac vaccine among students of Krasnodar. Methods. 119 seronegative students (18-30 years old) were examined. SARS-CoV-2 IgG (ELISA method) was determined 1, 3, and 6 months after two completed rounds of vaccination. Post-vaccination adverse events and COVID-19 cases were evaluated in the study. Results. SARS-CoV-2 IgG level 1 month after vaccination ranged from 6.15 to 19.38 and was to 16.39 (AU/mL) ± 1,12. Immunological potency values ranged from 4.407 to 21.5 (AU/mL) (14.74 ± 2.93) 3 months after. IgG titers were in the range of 4.14 to 17.71 (AU/mL) (10.97 ± 4.69) 6 months after. Adverse events after vaccination were revealed in 34 respondents (28.6%). Among them, local (hyperemia, pain, edema) — 21 (17.6%): slight — 90.4%, major — 9.6%; general (fever, weakness, algor, headache, arthralgia, myalgia) — 13 (10.9%): slight — 69.2%, major — 30.8%. The increase in vaccination coverage in students from 30.3 to 79.1% reduced the COVID-19 morbidity from 3.81 to 1.57%. Conclusion. Gam-COVID-Vac vaccine induced stable humoral response, demonstrated sufficient safety, and reduced morbidity 2.4-fold.

1. WHO Coronavirus (COVID-19) Dashboard. As of 30 January 2022. Available online: https://covid19.who.int. Accessed on April 17, 2022.

2. Sutovskaya DV, Burlutskaya AV, Dubova LV, Krylova DR. Immunological Protection of Individuals Aged 3 to 25 Years Against Pertussis: Regional Cross-Sectional Study. Voprosy sovremennoi pediatrii — Current Pediatrics. 2021;20(1):62-66. (In Russ). doi: https://doi.org/10.15690/vsp.v20i1.2237

3. Gonzalez S, Olszevicki S, Salazar М, et al. Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina. EClinicalMedicine. 2021;40:101126. doi: https://doi.org/10.1016/j.eclinm.2021.101126

4. Drapkina OM, Ryzhakova LN, Shishkova VN, et al. First real-world experience of Gam-COVID-Vac Sputnik V vaccine use. Profilakticheskaya Meditsina. 2021;24(10):53-60. (In Russ). doi: https://doi.org/10.17116/profmed20212410153

5. Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-681. doi: https://doi.org/10.1016/s0140-6736(21)00234-8

6. Coronavirus (COVID-19) Vaccinations. In: Our World in Data. Available online: https://ourworldindata.org/covid-vaccinations. Accessed on April 17, 2022.

7. Uglanova NN, Mushnikov DL, Polyakov BA. Knowledge level and motivation to COVID-19 prevention in medical students // Bulletin of the Ivanovo Medical Academy. 2020;25(3-4):11-14. (In Russ).

8. Shapovalov KG, Stepanov AV, Burdinskaya JS, et al. Three-month results of vaccination of monostationary health workers with the drug “Gam-Covid-Vac”. Immunologiya. 2021;42(2):125-130. (In Russ). doi: https://doi.org/10.33029/0206-4952-2021-42-2-125-130

9. Gentile A, Castellano VE., Weinberger N, et al. SARS-CoV-2 Antibody Response Following SPUTNIK V Vaccination in Healthcare Workers From a Hospital in Argentina: Preliminary Results. SSRN Electronic Journal. 2021. doi: https://doi.org/10.2139/ssrn.3929409

10. Drapkina OM, Berns SA, Gorshkov AYu, et al. Longterm dynamics of the levels of antiSARSCoV2 Sprotein IgG antibodies in vaccinated individuals. Cardiovascular Therapy and Prevention. 2021;20(8):23-28. (In Russ). doi: https://doi.org/10.15829/1728880020213124

11. Montalti M, Solda G, Di Valerio Z, et al. ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance. EClinicalMedicine. 2021;38:101027 doi: https://doi.org/10.1016/j.eclinm.2021.101027